Quality by design aided self-nano emulsifying drug delivery systems development for the oral delivery of Benidipine: Improvement of biopharmaceutical performance

AbstractThe primary objective of the research effort is to establish efficient solid self-nanoemulsifying drug delivery systems (S-SNEDDS) for benidipine (BD) through the systematic application of a quality-by-design (QbD)-based paradigm. Utilizing Labrafil M 2125 CS, Kolliphor EL, and Transcutol P,...

Full description

Saved in:
Bibliographic Details
Main Authors: Sheetal S. Buddhadev (Author), Kevinkumar C. Garala (Author), Saisivam S (Author), Mohamed Rahamathulla (Author), Mohammed Muqtader Ahmed (Author), Syeda Ayesha Farhana (Author), Ismail Pasha (Author)
Format: Book
Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_4c3b6635d0654f1285b7f6b2f7fe34b2
042 |a dc 
100 1 0 |a Sheetal S. Buddhadev  |e author 
700 1 0 |a Kevinkumar C. Garala  |e author 
700 1 0 |a Saisivam S  |e author 
700 1 0 |a Mohamed Rahamathulla  |e author 
700 1 0 |a Mohammed Muqtader Ahmed  |e author 
700 1 0 |a Syeda Ayesha Farhana  |e author 
700 1 0 |a Ismail Pasha  |e author 
245 0 0 |a Quality by design aided self-nano emulsifying drug delivery systems development for the oral delivery of Benidipine: Improvement of biopharmaceutical performance 
260 |b Taylor & Francis Group,   |c 2024-12-01T00:00:00Z. 
500 |a 10.1080/10717544.2023.2288801 
500 |a 1521-0464 
500 |a 1071-7544 
520 |a AbstractThe primary objective of the research effort is to establish efficient solid self-nanoemulsifying drug delivery systems (S-SNEDDS) for benidipine (BD) through the systematic application of a quality-by-design (QbD)-based paradigm. Utilizing Labrafil M 2125 CS, Kolliphor EL, and Transcutol P, the BD-S-SNEDDS were created. The central composite design was adopted to optimize numerous components. Zeta potential, drug concentration, resistance to dilution, pH, refractive index, viscosity, thermodynamic stability, and cloud point were further investigated in the most efficient formulation, BD14, which had a globule size of 156.20 ± 2.40 nm, PDI of 0.25, zeta potential of −17.36 ± 0.18 mV, self-emulsification time of 65.21 ± 1.95 s, % transmittance of 99.80 ± 0.70%, and drug release of 92.65 ± 1.70% at 15 min. S-SNEDDS were formulated using the adsorption process and investigated via Fourier transform infrared spectroscopy, Differential scanning calorimeter, Scanning electron microscopy, and powder X-ray diffraction. Optimized S-SNEDDS batch BD14 dramatically decreased blood pressure in rats in contrast to the pure drug and the commercial product, according to a pharmacodynamics investigation. Accelerated stability tests validated the product's stability. Therefore, the development of oral S-SNEDDS of BD may be advantageous for raising BD's water solubility and expanding their releasing capabilities, thereby boosting oral absorption. 
546 |a EN 
690 |a Benidipine 
690 |a solid self-nanoemulsifying drug delivery systems 
690 |a S-SNEDDS 
690 |a ternary phase diagram 
690 |a central composite design 
690 |a CCD 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Delivery, Vol 31, Iss 1 (2024) 
787 0 |n https://www.tandfonline.com/doi/10.1080/10717544.2023.2288801 
787 0 |n https://doaj.org/toc/1071-7544 
787 0 |n https://doaj.org/toc/1521-0464 
856 4 1 |u https://doaj.org/article/4c3b6635d0654f1285b7f6b2f7fe34b2  |z Connect to this object online.